Viatris Inc. (NASDAQ:VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 14, 2025 11:15 AM ET
Company Participants
Scott Smith – CEO
Doretta Mistras – CFO
Philippe Martin – Chief R&D Officer
Corinne Le Goff – Chief Commercial Officer
Conference Call Participants
Chris Schott – JPMorgan
Chris Schott
Good morning, everybody. I’m Chris Schott at JPMorgan, and it’s my pleasure to be hosting a fireside chat today with Viatris. From the company we’re going to have a quick presentation from CEO, Scott Smith, and then we’re going to have a broader Q&A session with the rest of the management team. So with that over to you, Scott.
Scott Smith
Thank you very much, Chris, and welcome everybody. And good morning to everybody here and on the webcast. I’m going to be making a couple comments before we get into the Q&A, which will be the bulk of the presentation. But I just wanted to, first show forward-looking statement and just let everybody know that we will not be commenting on full year 2024 or providing guidance in 2025 during this presentation.
Next slide, please. Just for those who aren’t familiar with Viatris, just a little snapshot of the company. We are a very strong global, diverse company operating around the world. In the last 12 months, $15 billion in revenue, $4.8 billion in adjusted EBITDA, $2.4 billion in free cash flow, tremendous financial strength in the company. Not only do we have a strong global generics business, but we are also home to some of the most iconic brands in the pharma world, The Lipitor, Lyrica, Celebrex, Norvasc, Viagra, many, many very important global brands that we own and we’re the home of, which is a very important aspect of our company.
From a geographic perspective, we operate in a 165
Read the full article here
